Mirikizumab达到溃疡性结肠炎研究的主要终点

2021-03-18 Allan MedSci原创

溃疡性结肠炎(UC)是大肠的一种慢性疾病,常常使人衰弱,并影响全球数百万人。UC的症状可能包括血液和粘液引起的慢性腹泻、腹痛和绞痛以及体重减轻。UC可以对工作、家庭和社交活动产生重大影响。

溃疡性结肠炎(UC)是大肠的一种慢性疾病,常常使人衰弱,并影响全球数百万人。UC的症状可能包括血液和粘液引起的慢性腹泻、腹痛和绞痛以及体重减轻。UC可以对工作、家庭和社交活动产生重大影响。

礼来公司的抗IL-23p19单克隆抗体(mAb)mirikizumab在III期溃疡性结肠炎(UC)研究中达到了主要终点和所有关键的次要终点。为期12周的LUCENT-1诱导研究评估了mirikizumab治疗中重度UC患者的有效性和安全性。

在LUCENT-1试验中,与安慰剂相比,mirikizumab在第12周达到了临床缓解的主要终点。这意味着结肠的炎症得到控制或解决,导致症状正常化或接近正常化。此外,mirikizumab在第12周达到了所有主要次要终点,这包括减少肠急症、临床反应、内镜缓解、症状缓解和内镜组织学炎症的改善。

Mirikizumab还在开始治疗后的4周内就表现出患者症状的快速改善,并且减轻了先前对生物制剂或Janus激酶(JAK)抑制剂疗法无反应或已停止反应的患者的症状。

礼来公司免疫学发展副总裁Lotus Mallbris说:“患有UC的人们通常很难有效地控制这种疾病的复发。有了这些积极的结果,我们希望这项研究能够持续52周,以提供更多数据”。

 

原始出处:

http://www.pharmatimes.com/news/lillys_mirikizumab_hits_primary_endpoint_in_ulcerative_colitis_study_1365367

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-09-05 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-06-16 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2022-02-28 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-07-30 DR.Fu SIR

    值得学习和借鉴经验!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-03-21 Surgeon L

    666

    0

相关资讯

英夫利昔单抗对难治性溃疡性结肠炎的疗效“更佳”

圣迭戈(EGMN)——在医院医学会年会上,加州大学圣迭戈分校的胃肠病学家Derek R. Patel博士指出,英夫利昔单抗是重度急性激素难治性溃疡性结肠炎(UC)的最佳补救治疗。   在一项随机研究中,Laharie博士及其同事比较了56例接受英夫利昔单抗治疗的激素难治性UC患者和55例接受环孢菌素治疗的相似患者,结果显示各组1周内的有效率均约为85%。随访第3个月时,环孢菌素组和英

拓展阅读

Nat Commun:中国药科大学胡庆华等团队合作发现溃疡性结肠炎治疗的潜在新靶点

该研究阐明了P2Y14R参与溃疡性结肠炎的一个未知机制,为炎症性肠病提供了一个有前景的治疗靶点。

J Ethnopharmacol:半夏泻心汤调节肠道菌群及肠道菌群代谢减轻溃疡性结肠炎

揭示半夏泻心汤(BXD)对溃疡性结肠炎(UC)的有益影响与肠道菌群组成之间的相关性。

ECCO 2024:乌司奴单抗治疗溃疡性结肠炎的短期和长期有效性与安全性:ULISES 研究

即使是难治性溃疡性结肠炎患者,乌司奴单抗也能有效诱导病情缓解。有部分患者中断了治疗,主要原因是初治失败和失去应答。在失去应答后,增加剂量可能会有效恢复应答,其安全性与之前的报告相似。

Gut:1岁时的优质饮食可能会抑制患炎症性肠病的风险

饮食质量高的 1 岁儿童,尤其是大量摄入鱼类和蔬菜的儿童,未来患 IBD 的风险降低。相比之下,在生命早期摄入含糖饮料与IBD风险增加有关。

Aging:痛泻要方通过调节MAPK/AKT信号通路治疗溃疡性结肠炎的网络药理学研究

探讨痛泻药方(TXYF)对溃疡性结肠炎(UC)的作用机理。

GIE:低氧成像结肠镜在溃疡性结肠炎疾病活动度客观测量中的临床应用

通过缺氧成像结肠镜获得的StO2可用于评估UC的临床、内镜和组织学活动,提示StO2可能是一种新的客观的内镜测量方法。